AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06538389 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study NCT06538389 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05293119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAK-2 inhibitor
Description: In this trial, one group will receive the tofacitinib 5 mg twice daily
Study NCT05293119 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical corticosteroid
Description: Mometasone furoate 0.1% ointment once daily
Study NCT06196437 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Participants will receive acupuncture.
Study NCT06196437 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: Participants will receive sham acupuncture.
Study NCT06476353 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Analysis of Force and Pressure Requirements across Syringe Sizes for Pain Management Procedures
Description: The investigators are analyzing the compression force required to plunge different syringe sizes to determine the operator's burden.
Study NCT05696756 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Web-based training for EMMA app
Description: Participants will complete six sessions of training to support uptake and habit formation of EMMA app use with a personalized web-based training platform.
Study NCT05696756 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Personalized Web-based training for EMMA app
Description: Participants will complete six sessions of training to support uptake and habit formation of EMMA app use with a personalized web-based training platform.
Study NCT05696756 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing: Clinician Support
Description: Participants will receive weekly brief check-ins with clinicians to motivate and support the problem-solving and habit formation aspects of the web-based training.
Study NCT06538389 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06405750 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: left atrial appendage closure
Description: systematic closure of the left atrial appendage in addition to the planned heart surgery
Study NCT05471154 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Definition transcranial direct current stimulation (HD-tDCS)
Description: HD-tDCS is used at 2mA and during 20 minutes and with electrodes positioned on regions F4 (anode), Fp2, Fz, F8 and C4 (cathodes), according to the international 10-20 electroencephalogram system. 5 sessions are given on 5 following days. The material used in this study is the Soterix Medical 1x1 tES mini-CT and HD 4x1 splitter, produced by Soterix Medical Inc., 237 W 35th St, New York, NY 10001, United States of America.
Study NCT05471154 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: High Definition transcranial direct current stimulation (HD-tDCS)
Description: HD-tDCS is used at 2mA and during 20 minutes and with electrodes positioned on regions F4 (anode), Fp2, Fz, F8 and C4 (cathodes), according to the international 10-20 electroencephalogram system. 5 sessions are given on 5 following days. The material used in this study is the Soterix Medical 1x1 tES mini-CT and HD 4x1 splitter, produced by Soterix Medical Inc., 237 W 35th St, New York, NY 10001, United States of America.
Study NCT04290871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide Gas
Description: Inspired NO/N2 will be delivered at 80 parts per million (ppm) in the first 48 hours of enrollment (within 48 hours after initiation of mechanical ventilation). Weaning from NO will start after 48-h consecutive NO inhalation. The physicians will follow their own institutional weaning protocols.
Study NCT06108817 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information material
Description: The intervention consists of the distribution of a poster for the waiting room and flyers to be given to patients aiming to inform both patients and GPs with respect to the correct indications for treatment of dyspepsia. After signing up, practices assigned to the intervention group received a package containing 60 flyers and one waiting room poster to use during consultations. The flyer and poster provide a short description of the correct indications for treatment of dyspepsia. Additionally, both the flyers and posters contained a QR-code linking to a decision aid explaining the correct indications and causes of dyspepsia.
Study NCT06108817 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Intervention
Description: These practices do not receive information material
Study NCT04290871 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: The delivery system will be set up anyway without study gas administration
Description: The delivery system will be set up anyway without study gas administration
Study NCT03033472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 600 mg Clindamycin orally
Description: 600 mg Clindamycin orally 30 minutes before treatment
Study NCT03033472 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Placebo
Description: Oral Placebo 30 minutes before treatment
Study NCT06180655 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Self-Management Education and Support (DSMES) plus Tai Chi Easy (TCE)™
Description: Participants will be asked to attend 45 minutes of DSMES and 45 min of TCE twice a week for 6 weeks. All classes will be recorded and available online and can viewed at a time when it is most convenient to accommodate working adults.
Study NCT04718363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF stretching
Description: A contract-relax PNF stretching technique will be applied to hamstring muscle.
Study NCT04718363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-vibration foam rolling prior to PNF stretching
Description: Prior to PNF stretching, participant will perform unilateral hamstring non-vibration foam rolling.
Study NCT04718363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vibration foam rolling prior to PNF stretching
Description: Prior to PNF stretching, participant will perform unilateral hamstring vibration foam rolling (48 Hz).
Study NCT05579509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam and Fentanyl
Description: Prior to the start of the nerve block, patients in Arm 1 will receive titrated pharmacological sedation with IV midazolam with a goal of achieving moderate sedation. If pain is felt despite subcutaneous lidocaine, IV fentanyl may be administered with a goal of achieving moderate sedation with analgesia.
Study NCT05579509 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Reassurance
Description: Patients in the nonpharmacologic group will receive intraprocedural education and reassurance without pharmacologic sedation. They will have the option to receive more pharmacologic sedation at any point during the nerve block (cross-over to titrated sedation group).
Study NCT04746495 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will go through a 2-week wash-in period. During the wash-in period, the participant will be asked not to take their usual antihypertensive medications for their mild hypertension. After the 2-week wash-in period, the participants will begin a 4-week treatment period and will take a placebo once a day for 4 weeks. After the 4 weeks, the participants will have a 2-week wash-out period where they will be off the study treatment. After the 2-week wash-out period, the participants will begin the Eplerenone treatment for another 4 weeks.
Study NCT04746495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone 50mg
Description: Participants will go through a 2-week wash-in period. During the wash-in period, the participant will be asked not to take their usual antihypertensive medications for their mild hypertension. After the 2-week wash-in period, the participants will begin a 4-week treatment period of Eplerenone for 4 weeks. After the 4 weeks, the participants will have a 2-week wash-out period where they will be off the study treatment. After the 2-week wash-out period, the participants will then begin the Placebo treatment for another 4 weeks.
Study NCT04469101 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Epidural
Description: Parturients will have an epidural placed in the upright seated position as per institution standard. After epidural placement, they will be positioned as per their randomization. They will then have a total of 20 cc of epidural solution (0.08% ropivacaine with 2 mcg per cc of fentanyl) injected into the epidural in boluses of 5 cc every 5 minutes.
Study NCT04973527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of LCAR-T2C CAR-T cells
Description: CD4-directed CAR-T cells administered with lymphoid depletion, and to obtain the preliminary efficacy results in subjects who have been diagnosed with relapsed or refractory CD4 positive T lymphocyte tumor
Study NCT05157412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg Oral Tablet
Description: Oral Doxycycline will be added to prednisolone as a comparison to using prednisolone as a sole therapy for the treatment of nasal polyps associated with chronic rhinosinusitis
Study NCT05157412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone 20 mg
Description: Prednisolone will be used in both arms as a sole therapy in one and together with doxycycline in the other
Study NCT05157412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone 20 mg
Description: Prednisolone will be used in both arms as a sole therapy in one and together with doxycycline in the other
Study NCT05081037 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable Care Group
Description: Continous glucose monitoring sensor: Study participants wear the sensor on the back of either right or left upper arm for up to 14 days. Glucose levels will be recorded from the interstitial fluid every 15 minutes using intermittent/ flash glucose scanning.~Exercise tracker: A FitBit watch will be given to the participants for use to track physical activity levels.
Study NCT05115760 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement
Description: Given Kate Farms pea protein oral nutrition supplement PO
Study NCT05115760 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05115760 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05128656 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: serology
Description: serology at M3 and serology at M6
Study NCT05868707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OH2
Description: Oncolytic Type 2 Herpes Simplex Virus
Study NCT05868707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salvage chemotherapy or best supportive care
Description: single or combined, including but not limited to dacarbazine, temozolomide, taxoid, or platinum
Study NCT05033795 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Water A
Description: 2 L of water A per day
Study NCT05033795 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Water B
Description: 2 L of water B per day
Study NCT04706065 — intervention group
Intervention type: GENETIC
Intervention: SHMT1 polymorphism
Description: It is to identify the role of SHMT1polymorphism in PD and examine the relationship between it and Severity of PD.
Study NCT05696665 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: Patients will be kept on conventional therapy and no added drugs will be given
Study NCT05696665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saffron and Chamomile
Description: Patients will be given saffron and chamomile in capsule formulation twice daily
Study NCT05696665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crocin and Apigenin
Description: Active ingredients of saffron(Crocin) and Chamomile(Apigenin) will be given in capsule formultaion once daily
Study NCT05117658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HA121-28 tablet
Description: HA121-28 tablet, 450 mg, po, QD×21 days, every 4 weeks (28 days)
Study NCT06510257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reconyl
Description: 1 tablet of Reconyl, 3 times daily
Study NCT06510257 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet of Reconyl
Description: 1 tablet of placebo Reconyl, 3 times daily
Study NCT05208710 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with PANHPVAX 10µg
Description: Escalated dosages of c-di AMP (0, 7,5, 15µg) added groupwise to 10µg antigen
Study NCT05208710 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with PANHPVAX 40µg
Description: Escalated dosages of c-di AMP (0, 7,5, 15µg) added groupwise to 40µg antigen
Study NCT05208710 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with PANHPVAX 100µg
Description: Escalated dosages of c-di AMP (0, 7,5, 15µg) added groupwise to 100µg antigen
Study NCT05284162 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health coaching
Description: The health coaching program includes four monthly health coaching sessions for three months.
Study NCT05143489 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preservative Free Lidocaine
Description: The patient will receive a 1mg/kg IV dose of lidocaine with a max dose of 40mg.
Study NCT05143489 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: The patient will receive IV normal saline of 1mg/kg with a max of 40mg
Study NCT05079711 — intervention group
Intervention type: DEVICE
Intervention: SavvyCheck Vaginal Yeast Test (rapid, point-of-care diagnostic test)
Description: The SavvyCheck Vaginal Yeast Test is a lateral flow immunochromatographic qualitative test for detection of Candida antigen in vaginal secretions, sampled by a swab as an aid for identification of vulvovaginal candidiasis (VVC), as a primary cause of vaginal yeast infections. The SavvyCheck Vaginal Yeast Test is designed for use by women experiencing vaginal symptoms, including: increased vaginal discharge, vaginal itching, vaginal soreness and irritation, rash on the labia, and genital burning that may worsen during urination. The SavvyCheck Vaginal Yeast Test is indicated for OTC use.
Study NCT02014428 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Study NCT02014428 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT05049395 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula oxygen (HFNO)
Description: The AIRVO2 is set at 30L/min, FiO2 100%, and 37℃ before anesthesia induction，and then 60L/min until the end of the procedure of sedated hysteroscopy.
Study NCT05049395 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Regular oxygen
Description: The patients are administered oxygen of 3L-6L/min until the end of the hysteroscopy operation.
Study NCT05575193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: The patients will receive 4 acupuncture points, including Quchi acupoint, Xuehai acupoint, Sanyinjiao acupoint, and Zusanli acupoint. Each acupoint will be pressed for 3 minutes, and totally 4 acupuncture points are 12 minutes.
Study NCT05767840 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psychological interventions
Description: mhGap-IG Depression and self-harm module. For participants identified as has having depression, following interventions will be offered depending on nature of the participants.~1. Khushi Aur Khatoon - for the treatment of depression and anxiety~2. Learning through Play Plus - 10-session group intervention that integrates parental information about child development and Cognitive Behavior Therapy~3. Problem management Plus (PM+) - PM+ is for adults suffering from symptoms of common mental health problems , as well as self-identified practical problems.~Cohort identified as having a recent history of self-harm will receive; Culturally Adapted Manual Assisted Problem Solving Intervention (CMAP) - This intervention is a manual-assisted intervention, adapted from a self-help guide called Life After Self-Harm.
Study NCT04730791 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Algo(s)rithm/ IASP clinical criteria
Description: IASP clinical criteria for identifying nociplastic pain. The criteria is completed by the healthcare professional and includes questions about the patient's clinical picture.
Study NCT04730791 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pressure Pain Threshold
Description: The pain pressure threshold (PPT) is used to measure pain sensitivity in body areas. The test quantifies the minimum amount of pressure in a given area, during an increasing skin pressure stimulus, which is capable of altering the feeling of pressure in pain.
Study NCT05195541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CU-20401
Description: Subcutaneous injection in the subcutaneous fat area，0.2ml
Study NCT05195541 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CU-20401
Description: Subcutaneous injection in the subcutaneous fat area，0.2ml
Study NCT05037565 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed guar gum
Description: Partially hydrolyzed guar gum (PHGG) is a vegetal, water soluble, non-viscous, non-gelling dietary fiber that is derived from guar gum, a water-soluble, viscous, gelling polysaccharide found in the seeds of Cyamopsis tetragonolobus. PHGG is available over the counter as a dietary supplement as fiber.
Study NCT05028504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penpulimab
Description: Penpulimab is a humanized monoclonal antibody targeting programmed cell death-1 (PD-1), which prevents PD-1 from binding to PD-L1 and PD-L2 receptors on tumor cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
Study NCT05028504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: A multi-target receptor tyrosine kinase inhibitor
Study NCT06137443 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balance Training
Description: Patients underwent treatment for eight weeks, with walking and balance exercises on Andago performed three days a week. In addition, conventional in-bed exercises, including stretching, strengthening, and mobility exercises, were administered for 40 minutes, two days a week.
Study NCT06523322 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Let's Cook Together
Description: The 8-week Let's Cook Together program is intended to increase: caregiver knowledge of the benefits of a whole foods approach to eating; preparedness for caregiving; and caregiver self-efficacy for managing patients' nutrition-related side effects. The entire program will be delivered remotely. Caregivers will be recruited to participate in an 8-week remote culinary medicine intervention, including four remote synchronous culinary workshops (one 90-minute introductory event and three, 90-minute culinary/cooking sessions), and four bi-weekly caregiver coaching telephone calls (lasting 15-20 minutes).
Study NCT06363552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC0191
Description: The SC0191 tablet is taken orally at a dose of 300mg once daily. Each treatment cycle consists of 28 days. Medication is administered on days 1 to 3, days 8 to 10, days 15 to 17, and days 22 to 24 of each cycle.
Study NCT06363552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC0191 + Bevacizumab
Description: 1. The SC0191 tablet is taken orally at a dose of 300mg once daily. Each treatment cycle consists of 28 days. Medication is administered on days 1 to 3, days 8 to 10, days 15 to 17, and days 22 to 24 of each cycle.~2. Bevacizumab injection is administered intravenously at a dose of 5mg/kg on day 1 and day 15 of each treatment cycle.
Study NCT06363552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC0191 + 5-FU/LV
Description: 1. The SC0191 tablet is taken orally at a dose of 300mg once daily. Each treatment cycle consists of 28 days. Medication is administered on days 1 to 3, days 8 to 10, days 15 to 17, and days 22 to 24 of each cycle.~2. Calcium folinate 400mg/m2 intravenous infusion (over 2 hours or more), on the first day, followed by 5-fluorouracil 400mg/m2 intravenous bolus injection, then continuous intravenous infusion of 1200mg/m2/day for 2 days.
Study NCT05016570 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Picture narrative information format
Description: Lung screening information formatted as picture narratives
Study NCT05016570 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text with pictures information format
Description: Lung screening information formatted as text and non-narrative pictures
Study NCT05016570 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text-only information format
Description: Lung screening information formatted as text with no pictures